Initiate a Phase 2 proof-of-concept study of VX-147 for APOL1-mediated kidney disease
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 30 Oct 2019
- Due
- 31 Dec 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Pending the results of the Phase 1 study, Vertex plans to initiate a Phase 2 proof-of-concept study in 2020 to evaluate the ability of VX-147 to reduce protein levels in the urine.”
What we found
Evidence strength A What the grades mean
The 2021 10-K states the company initiated the Phase 2 proof-of-concept trial of VX-147 in 2020, within the stated deadline year.
-
A Vertex Pharmaceuticals 10-K filed 2021-02-11
“In 2020, we initiated a Phase 2 proof-of-concept clinical trial for VX-147, our first investigational oral small molecule medicine” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2021-02-11
“In 2020, we initiated a Phase 2 proof-of-concept clinical trial designed to evaluate the reduction in proteinuria in people with APOL1-mediated FSGS after treatment with VX-147.” ✓ confirmed on the page
Market reaction: the shares moved -1.6% against the S&P 500 over the three sessions around the disclosure (10 Feb 2021 to 16 Feb 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 proof-of-concept study of VX-147
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: pending the results of the Phase 1 study
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2019-VRTX-006473 · Corrections policy